Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079

MODERNA, INC.

(MRNA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Moderna CEO says vaccines likely less effective against Omicron - FT

11/30/2021 | 12:50am EST

* Drugmaker CEO warns of "material drop" in vaccine effectiveness

* Mutations mean existing vaccines likely need modifying - CEO

* Financial markets drop

SYDNEY, Nov 30 (Reuters) - The head of drugmaker Moderna said COVID-19 vaccines are unlikely to be as effective against the Omicron variant of the coronavirus as they have been previously, sparking fresh worry in financial markets about the trajectory of the pandemic.

"There is no world, I think, where (the effectiveness) is the same level... we had with Delta," Moderna Chief Executive Stéphane Bancel told the Financial Times https://www.ft.com/content/27def1b9-b9c8-47a5-8e06-72e432e0838f in an interview.

"I think it's going to be a material drop. I just don't know how much because we need to wait for the data. But all the scientists I've talked to... are like 'this is not going to be good.'"

Vaccine resistance could lead to more sickness and hospitalisations and prolong the pandemic, and his comments triggered selling in growth-exposed assets like oil, stocks and the Australian dollar.

Bancel added that the high number of mutations on the protein spike the virus uses to infect human cells meant it was likely the current crop of vaccines would need to be modified.

He had earlier said on CNBC that it could take months to begin shipping a vaccine that does work against Omicron.

Fear of the new variant, despite a lack of information about its severity, has already triggered delays to some economic reopening plans and the reimposition of some travel and movement restrictions. [nL1N2SL045

(Reporting by Tom Westbrook; Editing by Kim Coghill)


ę Reuters 2021
All news about MODERNA, INC.
01/21Moderna's Valuation Has Come 'Back to Earth,' Become More Reasonable, BofA Securities S..
MT
01/21Boosters provide 'added protection' against Omicron -CDC
RE
01/21Small children getting less sick from Omicron; Genetic mutation protects against severe..
RE
01/21Booster shots needed against omicron, CDC studies show
AQ
01/21U.S. studies highlight the need for COVID boosters to fight Omicron
RE
01/21CDC : Vaccines less effective against Omicron, but still reduce risk for serious illness
AQ
01/21UBS Initiates Coverage on Moderna With Neutral Rating, $221 Price Target
MT
01/21BofA Securities Upgrades Moderna to Neutral From Underperform, Adjusts Price Target to ..
MT
01/20Moderna says aims to name 'country of choice' for COVID vaccine production in Africa so..
RE
01/20EMA Says Spikevax Product Information To Be Updated To Include Paraesthesia As Rare Sid..
RE
More news
Analyst Recommendations on MODERNA, INC.
More recommendations
Financials (USD)
Sales 2021 17 563 M - -
Net income 2021 11 122 M - -
Net cash 2021 9 774 M - -
P/E ratio 2021 6,05x
Yield 2021 -
Capitalization 64 900 M 64 900 M -
EV / Sales 2021 3,14x
EV / Sales 2022 2,05x
Nbr of Employees 1 300
Free-Float -
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MRNA | US60770K1079 | MarketScreener
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 19
Last Close Price 160,07 $
Average target price 276,00 $
Spread / Average Target 72,4%
EPS Revisions
Managers and Directors
StÚphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.-36.98%64 900
LONZA GROUP AG-15.65%52 307
IQVIA HOLDINGS INC.-14.60%46 031
SEAGEN INC.-17.50%23 323
ICON PUBLIC LIMITED COMPANY-18.65%20 508
CELLTRION, INC.-17.42%19 126